Year End Review Plus Manufacturer (CMO) Updates


    EDMONTON, Dec. 7 /CNW/ - "Research and development on our recombinant
protein Cyplasin-SC has been moved forward at a steady and strong pace over
the last year," states Garth Likes, President and CEO of Cyplasin. The
development of Cyplasin-SC was started in early March 2007 and since that time
the following product development milestones were achieved:

    -   Securing third party proof of concept of Cyplasin-SC in cell based
    -   Securing CRO partners for dosing ranging studies of Cyplasin-SC in
    -   Demonstration of first round efficacy of Cyplasin-SC in mice
    -   Sourcing of a CMO for pilot scale purification studies leading to
        larger scale GMP batch manufacture of Cyplasin-SC.

    With respect to the manufacturing strategy; of the four original
companies selected to submit quotes coming from countries from all around the
world, two have been selected which Cyplasin Biomedical feels would best fit a
successful completion of the tasks required. These two remaining contract
manufacturing organizations (CMOs) both with certified GMP-facilities, will
now enter into next stage negotiations with Cyplasin Biomedical Ltd, with a
final decision as to which CMO will manufacture for Cyplasin Biomedical being
taken before the end of next month.
    On a corporate development level Cyplasin Biomedical saw the launch of a
new web site and the issuance of a second USA patent covering expanded claims
for the manufacture and production of the recombinant protein Cyplasin-SC. The
Company also saw continued support from its investors and public markets as
Cyplasin Biomedical executed on its R&D and corporate development programs
resulting in strong shareholder value increases as reflected within its share
    "We expect to be able to continue this strong level of progress as
Company plans for next year include conclusion of discussions with a CMO for
production of Cyplasin, obtaining second efficacy validation in animals,
initiation of an FDA preclinical meeting leading to final toxicology studies
and an eventual filing of an IND allowing us to initiate human phase I
clinical studies," explained Professor Petzelt Cyplasin's CSO.
    Cyplasin-SC is being developed for use as an anticancer therapeutic drug
for melanoma and skin cancer.

    About Melanoma

    Around 160,000 new cases of melanoma are diagnosed worldwide each year.
Melanoma is more frequently found in Caucasian males and is more common in
Caucasian populations living in sunny climates than in other groups. Market
statistics for skin cancer and melanoma show that melanoma currently affects
more then 2.4 million people worldwide with 62,000 new cases being reported in
the USA every year. Australia has the highest rate of melanoma in the world
among males and has the second highest rate in the world among females
(Australia's Health 2004, AIHW). According to a WHO Report the world wide
incidence has doubled over the past 20 years with about 48,000 melanoma
related deaths occurring worldwide per annum.

    About Cyplasin-SC(TM)

    Cyplasin-SC(TM) has demonstrated a selective ability to rapidly kill
certain types of cancer cells while leaving normal non-cancerous cells
untouched. Cyplasin-SC(TM) is a protein originally discovered and isolated by
Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The
protein can now be manufactured as a recombinant protein which allows the
company to develop the protein as an anti-cancer therapeutic product. United
States and European Patents have been issued to the Company covering the
Cyplasin-SC(TM) protein.

    About Cyplasin Biomedical Ltd. (CBL)

    Founded in 2007 and headquartered in Edmonton, Canada with a research
laboratory close to Berlin, Germany, CBL is dedicated to bringing new
anticancer therapeutics to the marketplace. The Company's current goal is to
develop and commercialize the anticancer properties of Cyplasin-SC(TM) against
skin cancer and melanoma. CBL is publicly traded (CYPL: OTCBB)

    Forward-Looking Statements

    This Press release includes and is based, inter alia, on forward-looking
information and statements that are subject to risks and uncertainties that
could cause actual results to differ. Such forward-looking information and
statements are based without limitation, as statements regarding future drug
development activities, anticipated products, or anticipated future revenues,
benefits or advantages, and the future plans and objectives of the Company,
that involve inherent risks and uncertainties and are subject to factors, many
of which are beyond the Company's control, such as market acceptance of new
products and services, changes in governmental regulations, interest rates,
fluctuations in currency exchange rates and such other factors as may be
discussed from time to time that may cause actual results or performance to
differ materially from those currently anticipated in such statements. These
expectations, estimates and projections are generally identifiable by
statements containing words such as "expects", "believes", "estimates" or
similar expressions. Although Cyplasin Biomedical Ltd., believes that its
expectations and the information in this Press release were based upon
reasonable assumptions at the time when they were made, it can give no
assurance that those expectations will be achieved or that the actual results
will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no
representation or warranty, expressed or implied, as to the accuracy,
reliability or completeness of the information in the Press release, and
neither Cyplasin Biomedical nor any of their directors, officers or employees
will have any liability to you or any other persons resulting from your use of
the information in the Press release. The OTCBB Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of this news

For further information:

For further information: Garth Likes (CEO), Cyplasin Biomedical Ltd,
Tel.: (780) 469-2975, Fax: (780) 699-7933,; Professor
Christian Petzelt (CSO), Cyplasin Biomedical Ltd, Tel.: 0049-30-95992761,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890